(MedPage Today) — Clinicians face exciting new options in immunoglobulin A (IgA) nephropathy, with recent accelerated FDA approvals and positive data presented on agents targeting B-cell activating factor (BAFF) and a proliferation-inducing ligand…
Source link : https://www.medpagetoday.com/meetingcoverage/kidneyweekvideopearls/118987
Author :
Publish date : 2025-12-12 17:20:00
Copyright for syndicated content belongs to the linked Source.
